A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.

NCT Number	NCT06614751
Lead Sponsor	Danatlas Pharmaceuticals Co., Ltd
Conditions	Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Endometrial Cancer +3 more
Enrollment	112 participants
Start Date	2024-11-01
Primary Completion	2026-11-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-09-27